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Abstract 
The peritoneal surface remains an important failure site for patients with gastrointestinal 
and gynecologic malignancies. In the past, oncologists regarded peritoneal 
carcinomatosis as an incurable component of an intra-abdominal malignancy. During the 
last two decades, novel therapeutic approaches have emerged for peritoneal 
carcinomatosis patients. We report the first case of peritoneal carcinomatosis emerging 
from an extra-adrenal, intra-abdominal paraganglioma. This 49-year-old male was 
treated with cytoreductive surgery and hyperthermic intraperitoneal perioperative 
chemotherapy. Paragangliomas are rare tumors of neural crest-derived chromaffin cells 
and can originate either from the sympathetic or from the parasympathetic ganglia. It 
has been estimated that as many as 10% of the paragangliomas arise outside the adrenal 
glands. This case represents an unreported presentation of paraganglioma. Two possible 
origins of this malignancy, and the applied therapy, are discussed. We report the 
feasibility of cytoreductive surgery plus hyperthermic intraperitoneal perioperative 
chemotherapy in the treatment of this malignancy. 
 
Introduction 
The peritoneal surface remains an important failure site for patients with 
gastrointestinal and gynecologic malignancies [1, 2]. In the past, oncologists assumed that 
peritoneal carcinomatosis (PC) was equal to distant metastases and as such they regarded 
it as an incurable component of the intra-abdominal malignancy [3]. During the last two 
decades, novel therapeutic approaches have emerged for PC patients. Those treatments 
are based on a revised hypothesis that considers PC as a local-regional disease warranting 
a local-regional therapeutic approach [4]. An aggressive surgical approach combining 
visceral resections and peritonectomy procedures should address the macroscopic disease, 
whereas perioperative [intraperitoneal and/or intravenous (i.v.)] chemotherapy is aimed 
at residual microscopic disease. In 1980, Spratt et al. [5] reported the use of heated  
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triethylenethiophosphoramide in a patient with pseudomyxoma peritonei for the first 
time. Since then, one randomized trial and several phase II studies have explored the 
perioperative intraperitoneal route of drug delivery, with promising results [6–10]. 
Paragangliomas are rare tumors of neural crest-derived chromaffin cells and can 
originate either from the sympathetic or from the parasympathetic ganglia [11]. These 
tumors represent 10–18% of all chromaffin tissue-related tumors [11, 12]. It has been 
estimated that as many as 10% of the paragangliomas arise outside the adrenal glands 
[13]. 
We report the first case of PC due to paraganglioma and the application of 
cytoreductive surgery and intraperitoneal chemotherapy in this patient.  
Case Report 
Presentation 
A 49-year-old male presented with diffuse abdominal pain requiring minor analgesia. Obstructed 
defecation was present for five months. Appetite was normal and no nausea, vomiting or weight loss 
were reported. The clinical examination was within normal limits. Biochemistry revealed a hemoglobin 
level of 12.7 g/dl (reference range 13.1–17.2 g/dl) and a CRP level of 6.8 mg/dl (reference range <0.5 
mg/dl). Carcinoembryonic antigen level was within normal limits (<0.2 ng/ml; reference range 0–5 
ng/ml). 
Diagnostic Workup 
A plane X-ray of the abdomen described no abnormalities. Ultrasonography of the abdomen 
revealed a 17 × 19 cm semisolid tumor mass with cystic components caudally to the right lobe of the 
liver. The mass had a very irregular border and an inhomogeneous content. A subsequent computed 
tomography (CT) confirmed the 15 × 11 × 19 cm tumor mass with suggested signs of malignancy 
(tumor size, signs of necrosis, peritoneal metastasis) (fig. 1). There was evidence of peritoneal 
involvement and omental extension. The CT images also depicted a similar tumor nodule of 5 cm in 
diameter, localized in the cavum douglasi. Subsequent gastroscopy and left colonoscopy were normal. 
Positron emission tomography (PET) scan showed the abovementioned abdominal localizations. 
Treatment 
The patient underwent an explorative laparotomy and subsequent cytoreductive surgery, followed by 
HIPEC. First, the biggest peritoneal tumor mass was resected en bloc with the omentum, pancreatic 
capsule and a part of the pancreatic head. A right-sided diaphragmatic peritonectomy (according to 
Vazquez and Sugarbaker [14]) was carried out. The ligamentum umbilicale was excised up to the level 
of the left portal vein and a total peritonectomy of Morisson’s pouch was performed. A few peritoneal 
tumor nodules on the liver capsule were resected, followed by a partial resection of the peritoneum of 
the left diaphragma. Due to a big fixed nodule on the spleen, a splenectomy was done. Thereafter, a 
bursectomy of the bursa omentalis minor with excision of the omentum minus was completed. A few 
nodules (1 to 3 mm) on the mesentery of the small bowel were resected, but the bowel itself appeared 
normal. On the mesentery of the colon transversum we also resected some tumor nodules. The colon 
itself turned out to be normal, except in the cavum douglasi, which was obliterated by tumor tissue. We 
decided to perform an en bloc anterior resection and pelvic peritonectomy. Eventually, a CC-0–CC-1 
cytoreduction was achieved. 
Subsequent hyperthermic intraperitoneal perioperative chemotherapy (HIPEC) (open abdominal 
technique [15]) with cisplatinum (50 mg/m
2 for a total dose of 110 mg) and doxorubicin (15 mg/m
2 for 
a total dose of 33 mg) was initiated at 41.5°C for 90 min. A 2 liter/m
2 isotonic icodextrin carrier solution  
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(1.5%) was used. The i.v. component of the bidirectional intraoperative chemotherapy consisted of 5-
fluorouracil 880 mg (400 mg/m
2) i.v. and leucovorin 44 mg (20 mg/m
2), both administered via separate 
i.v. accesses. The patient tolerated the procedure well. The diuresis was kept above 2 ml/kg/h. The 
hyperglycemia due to the carrier fluid was countered with an insulin drip [16]. The total duration of the 
procedure was 14 h and 20 min. The postoperative stay was without complications. 
After nine months, no evidence of recurrent disease was detected. 
Pathology 
At macroscopy, the largest nodule showed extensive hemorrhage and some cyst-like areas (fig. 2). 
Histologically, the tumor had a mixture of spindle-shaped and syncytial growth pattern. Abundant 
vascular structures were present. The nodular groups of cells were divided by tiny fibrovascular axes, 
thus resembling a neuroendocrine tumor. The cells were monomorphic with an abundant eosinophilic 
or clear cytoplasm. Mitotic activity was mild. 
On immunohistochemical stainings, tumor cells were positive for synaptophysin (fig. 3) and 
vimentin. Few cells were positive for desmin. Staining for keratin, EMA, CK7, neurofilament, 
chromogranin, S-100, actin, CD34 and CD117 was negative. The S-100 staining was positive in some 
sustentacular cells. Proliferation marker Ki-67 was positive in 3% of tumor cells. Based on the 
morphological appearance and the immunohistochemical findings, an abdominal extra-adrenal 
paraganglioma was the most likely diagnosis. 
Other resected nodules (table 1) harbored metastases of the paraganglioma. 
Discussion 
A New Paradigm in the Treatment of PC 
The surface of the abdomen and pelvis are important anatomic sites for the 
dissemination of gastrointestinal and gynecologic malignancies. Tumor cells may 
exfoliate from the primary tumor into the peritoneal cavity preoperatively due to 
transserosal growth [17]. Alternatively, at the time of surgery, tumor cells can be 
dispersed from transected lymph or blood vessels, or by manipulation of the primary 
tumor. Once malignant cells are free inside the peritoneal cavity, they become trapped at 
sites of trauma where fibrin accumulations and blood clots will secure them and enhance 
their growth [18, 19]. Eventually, this may result in the development of clinical PC. The 
reported incidence in the literature varies widely. For example, in a review of 2,756 
patients by Jayne et al. [2], the incidence of PC at the time of initial surgery was reported 
to be 7.7%. A review of colonic cancer patients who had recurrences suggest that 
peritoneal seeding occurred in 25% to 35% of patients [20]. 
In the past, PC has long been considered a terminal disease stage with no curative 
treatment options. Chu et al. [3] were the first to investigate the impact of PC upon 
survival. In 100 patients with biopsy-proven PC, they reported a mean survival of 8.5 
months in colorectal cancer patients, 2.4 months in pancreatic cancer patients and 2.2 
months in gastric cancer patients. The European prospective multicenter trial EVOCAPE 
1 (Evolution of PC 1) reported remarkably similar results in nongynecologic malignancy 
patients with PC who received 5-fluorouracil-based systemic chemotherapy [1]. In 2002, 
Jayne et al. [2] reported a median survival of 7 months in colorectal cancer patients who 
had synchronous peritoneal implants. Some reliable data on this topic came from the  
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control arm of the phase III trial by Verwaal et al. [6]. A recent update of this trial 
revealed a median disease-specific survival of 12.6 months in patients with PC from 
colorectal cancer who received 5-fluorouracil-leucovorin-based systemic chemotherapy 
[7]. More recent systemic chemotherapy protocols based on the use of oxaliplatin, 
irinotecan and biologic agents have improved survival in colorectal cancer patients with 
PC. Elias et al. [8] reported a 23.9-months median survival in 48 colorectal cancer patients 
with small-volume carcinomatosis who were treated with systemic chemotherapy 
containing oxaliplatin or irinotecan. It is important to mention that no long-time 
survivors are reported in these series. 
During the last two decades, novel therapeutic approaches to PC have emerged, 
combining cytoreductive surgery and perioperative (intraperitoneal and/or i.v.) 
chemotherapy. The perioperative intraperitoneal chemotherapy includes HIPEC and/or 
early postoperative intraperitoneal chemotherapy (EPIC). Elias et al. [21] first reported 
the clinical use of intraoperative i.v. 5-fluorouracil and leucovorin in conjunction with 
oxaliplatin-based HIPEC in 2002. Most recent protocols advocate this bidirectional 
(simultaneous intraperitoneal and i.v. chemotherapy) intraoperative chemohyperthermy. 
Spratt et al. [5] reported, in 1980, the use of heated triethylenethiophosphoramide in a 
patient with pseudomyxoma peritonei for the first time. Since then one randomized 
controlled trial and several phase II studies have explored the perioperative 
intraperitoneal route of drug delivery. In an update on their phase III trial, Verwaal et al. 
[7] reported a 45% 5-year survival in colorectal PC patients receiving optimal 
cytoreduction and HIPEC with mitomycin C followed by systemic chemotherapy. Elias et 
al. recently analyzed the results of combined cytoreductive surgery and perioperative 
chemotherapy in 1,290 patients with PC due to a variety of primary malignancies [22]. 
After 5 years, 37% of these patients were still alive. These encouraging clinical results are 
in strong contrast with historical control groups and patients treated with systemic 
chemotherapy alone and there is no doubt that the clinical evidence in the medical 
literature supporting the combined approach of cytoreductive surgery and perioperative 
intraperitoneal chemotherapy is growing. 
The Paraganglioma 
Paragangliomas are rare tumors of neural crest-derived chromaffin cells and can 
originate either from the sympathetic or from the parasympathetic ganglia [11] (table 2). 
Approximately 25% of sympathetic-derived and 50% of parasympathetic-derived 
paragangliomas are inheritable [12]. The younger the patients are at the time of diagnosis, 
the more likely they are to have familial disease [23, 24]. 
The modes of presentation of paraganglioma may be divided into mass effect, 
incidental discovery and excess catecholamine production (classically with headache, 
palpitation, sweating, and episodic hypertension). In familial cases, genetic screening of 
family members is another common route for discovery [12]. Most head and neck 
paragangliomas are nonsecreting tumors [25]. 
Unlike pheochromocytomas, which have been classically described as having a 10% 
malignancy rate, intra-abdominal paragangliomas tend to be the most aggressive 
sympathetic-derived paragangliomas [12]. The incidence of malignancy ranges from 14%  
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to as high as 50%, depending on series [26]. These malignant tumors tend to spread 
hematogenously, lymphatically, and through local invasion [12]. Unfortunately, even final 
pathology does not reliably predict biological behavior [12]. 
Peritoneal Presentation of Extra-Adrenal Paraganglioma 
This case represents an unreported presentation of a paraganglioma. This extra-
adrenal, intra-abdominal paraganglioma could be the metastasis of a regressed primary 
tumor or it could be a primary, peritoneal presentation of an extra-adrenal 
paraganglioma. The first would be a case of cancer of unknown primary (CUP) origin. 
CUP is defined as biopsy-proven metastasis from a malignancy in the absence of an 
identifiable primary site after a complete clinical workup [27]. This entity is classified into 
several histological types and a paraganglioma would be a case of a neuroendocrine CUP. 
Prasad et al. [28] describe a series of 59 patients with documented neuroendocrine tumors 
and unknown primary. Using 68Ga-labeled (1,4,7,10-tetraazacyclododecane-
N,N′,N′′,N′′′-tetraacetic acid)-1-NaI3-octreotide (68Ga-DOTA-NOC) PET/CT, the site 
of the primary was localized in 35 patients, one of which had a primary paraganglioma. 
The other possibility of a primary extra-adrenal paraganglioma would be derived from 
chromaffin cells in the peritoneum. Based on anatomical distribution, extra-adrenal 
paragangliomas of the abdomen are divided into three major groups [28] (table 2). 
Freedman and Goldman [29] reported a case of a normal paraganglion in the 
mesosigmoid and emphasized the potential for a neoplastic paraganglioma to develop in 
this area and in other unusual locations. Sporadic cases of paragangliomas arising in 
locations outside the distribution of the autonomic nervous system, where normal 
paraganglionic tissue had not yet been characterized, have been described [28]. These can 
be explained by the dispersed migratory property of the neural crest [30]. Kudoh et al. 
[30] reported in 2005 what was, to their knowledge, only the seventh case of 
paraganglioma arising in the mesentery. They assumed that the mesenteric 
paraganglioma was derived from the paraganglionic cells by vertebral migration from the 
root of the superior mesentery artery. Based on these findings and on the pathologic 
characteristics of the tumor we present, we believed our patient to have a primary extra-
adrenal paraganglioma.  
Due to the unknown origin of the tumor mass before therapy, questions could arise 
about the rationale of the therapeutic approach. Based on all the examinations performed, 
a sarcoma was the most likely origin. The first step in therapy was cytoreduction because 
surgical resection is the treatment of choice for sarcoma [31, 32] and investigations 
revealed this was feasible. With the HIPEC containing cisplatin and doxorubicin as 
intraperitoneal components, we applied a chemotherapy regimen with cytotoxic effect 
against a wide variety of malignancies. In fact, among the drugs used so far for 
intraperitoneal chemotherapy, the combination of cisplatin and doxorubicin appears to 
be one of the most effective available regimens with acceptable local-regional toxicity [33]. 
On the other hand, doxorubicin is one of the most active antineoplastic drugs currently 
available against sarcoma [34] and some studies demonstrated in preclinical models that 
doxorubicin activity is enhanced by the addition of cisplatin and/or hyperthermia [35]. In 
order to fine-tune the intraoperative adjuvant therapy, an option could have been to use 
the intraoperative frozen-section examination, but the techniques used for the evaluation  
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of a sarcoma are immunohistochemistry and molecular genetic and cytogenetic 
investigation [36], so frozen-section examination would be unreliable. 
Knowing the results of the pathologic examination, other therapeutic options can now 
be suggested, although it is accepted that the mainstay of therapy for primary 
paraganglioma is complete surgical resection. For malignant, metastatic or unresecable 
paragangliomas, 
131I-metaiodobenzylguanidine (MIBG) is a well-documented treatment 
[12]. The norepinephrine transporter (NET) plays a key role in this treatment modality 
[37]. It is expressed on chromaffin cells of extra-adrenal paragangliomas and is used to 
incorporate 
131I-MIBG in tumor cells. In this way it can achieve significant therapeutic 
responses in malignant pheochromocytoma without biochemical toxicity and with only 
mild radiotoxicity [38, 39]. The use of traditional chemotherapeutic agents such as 
cisplatinum or doxorubicin was investigated to increase NET functional activity [37] and 
thus to augment the effectiveness of 
131I-MIBG therapy. For neuroblastoma, Meco et al. 
[40] suggested that the combination of 
131I-MIBG and cisplatinum or doxorubicin could 
selectively increase radiation doses delivered to neuroblastoma cells. However, there are 
probably intrinsic differences between the pheochromocytoma and neuroblastoma cell 
lines, as pretreatment of the rat pheochromocytoma PC12 cell line with cisplatinum does 
not increase the functional activity of the transporter [39]. Only sparse data on the use of 
chemotherapy against paraganglioma are presented in the literature. In 1988, Averbuch et 
al. [41] concluded that combination chemotherapy with cyclophosphamide, vincristine, 
and dacarbazine (CVD) is effective for advanced malignant pheochromocytoma. This 
chemotherapy regimen was recently confirmed in a review of Adjallé et al. [42]. 
Chemotherapy should be applied to patients without positive MIBG-scan, with no 
response to (
131)I-MIBG or progression after radionuclide treatment, and especially in 
cases with a high proliferation index. A number of case reports have been published using 
the same regimen for malignant paraganglioma [43–45]. A slightly different 
chemotherapy regimen was proposed in 1995 by Patel et al. [46]. The authors concluded 
that CVD chemotherapy is active in the treatment of patients with paraganglioma. 
Although there are thus a few possible chemotherapy regimens to treat inoperable 
paraganglioma, there is no consensus about them in the literature. Clinical studies 
indicate, however, that doxorubicin has a possible in vivo effect against paraganglioma. 
Role of Cytoreductive Surgery and HIPEC in PC with Paraganglioma Origin 
There is no doubt that cytoreductive surgery is the essential first step in the treatment 
of PC with paraganglioma origin. Not only the use of HIPEC, but also the specific 
intraperitoneal and i.v. components of the bidirectional, intraoperative chemotherapy 
remains uncertain. Phase-II clinical trials are needed to provide more supportive evidence 
but, due to the rarity of the disease, they are unlikely to happen. This report, together with 
findings in the literature, suggests a possible role for HIPEC in the treatment of PC with 
paraganglioma origin.  
Conclusion 
This report provides the first case of extra-adrenal, intra-abdominal paraganglioma 
PC. The optimal treatment of this malignancy has yet to be established. In our experience,  
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the combination of cytoreductive surgery and HIPEC is feasible. This treatment resulted 
in minor morbidity, no mortality and short-term disease-free survival. 
Table 1. Other specimens examined, containing all metastases of the big tumor mass 
Multiple peritoneal metastases 
Omentum 
Gall bladder (weight 34 g, length 8 cm) 
Liver metastasis 
Metastasis on liver capsule 
Peritonectomy of the left diaphragm 
Peritonectomy of the right diaphragm 
Spleen (weight 290 g) 
Bursa omentalis minor 
Omentum minus 
Metastasis in the mesocolon transversum 
Piece of mesenterium of the small bowel 
Right paracolic gutter 
Cecal metastases 
Resection piece of the anterior resection (length 25 cm) with pelvic peritonectomy 
 
 
Table 2. Origin and anatomic distribution of paragangliomas (neural crest-derived chromaffin cells) 
[12, 13, 26] 
1  Parasympathetic ganglia: almost exclusively in the neck and skull base  
2 Sympathetic  ganglia: 
  a  Adrenal medulla (pheochromocytoma): ±90% 
  b  Sympathetic paraganglioma (extra-adrenal pheochromocytoma): ±10%: along the sympathetic 
chain: 
   
  Area  Incidence 
  Cervical  03% 
  Intrathoracic  12% 
  Intra-abdominal  85% 
   Superior  para-aortic  45% 
   Inferior  para-aortic  30% 
   Urinary  bladder  10% 
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Fig. 1. CT-image. A 49-year-old male presented with diffuse abdominal pain requiring minor 
analgesia. Obstructed defecation was present for five months. CT-image demonstrated a 15 × 11 × 19 
cm tumor mass with signs of malignancy (tumor size, signs of necrosis, peritoneal metastasis). The 
mass was localized caudally to the right lobe of the liver. a: Frontal plane. b: Horizontal plane. 
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Fig. 2. Macroscopic image. Macroscopic perioperative image of large tumor mass. It is primary 
localized in the right upper abdominal quadrant and appears hemorrhagic and to some extent cystic 
(head of patient at the left side). 
 
 
 
Fig. 3. Microscopic image. Immunostain for synaptophysin shows paranuclear dots on a biopsy taken 
from the large tumor mass. 
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